Neuropace (NASDAQ: NPCE) insider transactions
In the twelve months to 10 November 2026, executives and directors of Neuropace reported 1 open-market sale of 25,000 shares ($399,250) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 24 September 2026 | Morrell Martha | Chief Medical Officer | Shares withheld for tax | −335 | $13.97 | 51,357 | Form 4 |
| 20 September 2026 | Williams Patrick F. | Chief Financial Officer | Shares withheld for tax | −1,162 | $14.28 | 67,508 | Form 4 |
| 3 September 2026 | Becker Joel | Chief Executive Officer | Shares withheld for tax | −1,310 | $14.75 | 138,000 | Form 4 |
| 27 August 2026 | Becker Joel | Chief Executive Officer | Shares withheld for tax | −1,126 | $14.13 | 139,310 | Form 4 |
| 27 August 2026 | Morrell Martha | Chief Medical Officer | Shares withheld for tax | −358 | $14.13 | 51,692 | Form 4 |
| 24 June 2026 | Morrell Martha | Chief Medical Officer | Shares withheld for tax | −335 | $16.22 | 52,050 | Form 4 |
| 19 June 2026 | Fischer Frank M | Director | Grant or award | +1,467 | $15.63 | 599,534 | Form 4 |
| 19 June 2026 | Geiger Uri | Director | Grant or award | +789 | $15.63 | 18,537 | Form 4 |
| 19 June 2026 | Kumar Rakhi | Director | Grant or award | +989 | $15.63 | 23,039 | Form 4 |
| 5 June 2026 | Fischer Frank M | Director | Grant or award | +2,890 | — | 598,067 | Form 4 |
| 5 June 2026 | Geiger Uri | Director | Grant or award | +2,890 | — | 17,748 | Form 4 |
| 5 June 2026 | Andrade Lisa | Director | Grant or award | +2,890 | — | 2,890 | Form 4 |
| 5 June 2026 | Huennekens R Scott | Director | Grant or award | +2,890 | — | 2,890 | Form 4 |
| 5 June 2026 | Ryan Renee | Director | Grant or award | +2,890 | — | 2,890 | Form 4 |
| 5 June 2026 | Kumar Rakhi | Director | Grant or award | +2,890 | — | 22,050 | Form 4 |
| 3 June 2026 | Becker Joel | Chief Executive Officer | Shares withheld for tax | −1,255 | $15.88 | 140,436 | Form 4 |
| 27 May 2026 | Becker Joel | Chief Executive Officer | Shares withheld for tax | −1,126 | $17.06 | 141,691 | Form 4 |
| 27 May 2026 | Morrell Martha | Chief Medical Officer | Shares withheld for tax | −358 | $17.06 | 52,385 | Form 4 |
| 15 May 2026 | Becker Joel | Chief Executive Officer | Grant or award | +45,880 | — | 142,817 | Form 4 |
| 15 May 2026 | Williams Patrick F. | Chief Financial Officer | Grant or award | +16,820 | — | 68,670 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Neuropace page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.